Clinical Trial Update: Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the combination of ruxolitinib and peg-interferon alfa-2a in patients with myelofibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• PEG-interferon alfa-2a (pegylated interferon alfa-2a)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Myelofibrosis | Phase 1, Phase 2 | Status: COMPLETED